Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
Financial Post·October 1, 2026
Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCM…
This article was sourced from Financial Post. Read the full article at the original publisher.
Read full article at Financial Post →